GlassScriptPhysician profile
Srikant Muddana
NPI 1629125448
$6,741.26
in general payments reported to CMS, 2019-2025
25 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $255 · 2021: $803 · 2022: $1,087 · 2023: $1,497 · 2024: $1,743 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,578 · Education: $18.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,577.93 |
| Education | $18.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,987.13 | 2020-2025 | |
| Janssen Biotech, INC. | $1,079.40 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $571.63 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $368.70 | 2020-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $193.76 | 2021-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $170.13 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $168.03 | 2025 | |
| Ferring Pharmaceuticals INC. | $159.19 | 2021-2023 | Rebyota |
| Pfizer INC. | $157.81 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $132.20 | 2021-2023 | |
| Ardelyx, INC. | $118.79 | 2023-2025 | Ibsrela |
| Sandoz INC. | $97.33 | 2024-2025 | Hyrimoz |
| Braintree Laboratories, INC. | $94.96 | 2020-2021 | |
| Redhill Biopharma INC. | $90.90 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $83.77 | 2024-2025 | Vowst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $66.21 | 2023-2025 | Omvoh |
| Organon LLC | $28.11 | 2023 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.05 | 2024 | Cyltezo |
| Madrigal Pharmaceuticals | $26.74 | 2024 | Resmetirom |
| Ironwood Pharmaceuticals, INC | $24.96 | 2020 | |
| Daiichi Sankyo INC. | $22.21 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $19.30 | 2022 | |
| Qol Medical, LLC | $18.54 | 2022 | |
| Celltrion USA INC. | $18.13 | 2024 | Yuflyma, Zymfentra |
| Merck Sharp & Dohme LLC | $15.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikant Muddana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.